News & Analysis as of

Samsung Biogen Idec

Goodwin

Biogen Sells Bioepis Stake for $2.3 Billion to Samsung Biologics

Goodwin on

Last week, Biogen Inc. announced it had reached an agreement to sell its equity stake in the Samsung Bioepis joint venture to partner Samsung Biologics for an aggregate consideration of up to $2.3 billion.  According to a...more

Goodwin

Biogen and Samsung BioLogics Close Asset Transfer Deal

Goodwin on

As we previously reported, Biogen has exercised its option to purchase additional shares of Samsung Bioepis, increasing Biogen’s ownership in the Samsung Bioepis joint venture from approximately 5.4% to approximately...more

Goodwin

Biogen Increases Ownership Stake in Samsung Bioepis

Goodwin on

As we previously reported, on April 24, 2018, Biogen announced that it had plans to exercise an option to acquire up to a 49.9% equity stake in Samsung Bioepis, its joint venture with Samsung BioLogics. Yesterday, Biogen...more

Goodwin

IPR Updates

Goodwin on

The PTAB remains a busy venue for biologics patents. Here are some IPR updates from the weeks since our last IPR update...more

Goodwin

Samsung Bioepis Presents New Biosimilars Data at EULAR 2016

Goodwin on

At the Annual European Congress on Rheumatology (EULAR 2016), held last week in London, Samsung Bioepis presented new clinical data on its etanercept, adalimumab, and infliximab biosimilars. According to a press release from...more

Patterson Belknap Webb & Tyler LLP

Enbrel Biosimilar in Europe and US

On November 19, 2015, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion, recommending marketing authorization of Benepali, the first biosimilar of Enbrel...more

6 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide